13F Pro quality score
Rank #2,677 of 2,884
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from INTELLIGENT BIO SOLUTIONS INC.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2026 | 10-K | $4.2M | $-12.4M | — |
| FY 2025 | 10-K | $3.1M | $-10.6M | — |
| FY 2024 | 10-K | $3.1M | $-10.2M | — |
| FY 2023 | 10-K | $1.3M | $-10.6M | — |
| FY 2022 | 10-K | $437.1K | $-8.3M | — |
| FY 2021 | 10-K | $2.0M | $-7.0M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
INTELLIGENT BIO SOLUTIONS INC. (INBS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INBS at 23.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,677 of 2,884 stocks — the bottom half of the AI-ranked universe. INBS scores in the top quartile across revenue growth (81.6). Areas of concern include balance sheet strength (1.0) and revenue scale (1.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), INTELLIGENT BIO SOLUTIONS INC. reports quarterly revenue of $1.1M, net income of $-3.9M, free cash flow of $-3.2M. Top institutional holders of INBS by reported 13-F value include ARMISTICE CAPITAL, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. INBS trades on the Nasdaq exchange and files with the SEC under CIK 1725430. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INBS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INTELLIGENT BIO SOLUTIONS INC. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1725430 →